Why Shares of Eli Lilly Soared This Week
Pfizer's deal with the Trump administration raised hopes that Eli Lilly would also avoid pharmaceutical tariffs.
MRK Stock Up Nearly 14% So Far This Week: What's Driving It?
Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity - Eli Lilly ( NYSE:LLY )
Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly ( NYSE:LLY ) revealed 18 unusual trades. Delving into the details, we found 50% of traders were bullish, while 22% showed bearish tendencies.
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?
Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.
3 Blue Chip Stocks That Have Soared 380% ( and Higher ) Over the Past 5 Years
By investing in quality growth stocks, you can put yourself in an excellent position to earn a great return.
Eli Lilly Shares Are Trading Higher Wednesday: What's Going On? - Eli Lilly ( NYSE:LLY )
Eli Lilly And Company ( NYSE:LLY ) shares are trading higher Wednesday after President Donald Trump recently announced a deal with Pfizer as well as the 'TrumpRx' site to decrease prices. What To Know: Pfizer agreed to provide medicines on the TrumpRx platform at steep discounts and extend ...
Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away - CVS Health ( NYSE:CVS ) , Eli Lilly ( NYSE:LLY ) , Pfizer ( NYSE:PFE ) , UnitedHealth Group ( NYSE:UNH )
Pfizer Inc's ( NYSE:PFE ) deal with Washington isn't just a handshake in the Oval Office - it's a seismic jolt to America's drug-pricing game.
Stock Market News for Oct 1, 2025
Wall Street closed higher on Tuesday, driven by healthcare stocks.
Stock Market Today: Pfizer Rallies on Trump Drug Pricing Deal and U.S. Investment Pledge
Pfizer surged after striking a landmark agreement with the Trump administration to lower drug prices and expand U.S. production.
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
Is Lilly ( LLY ) a Buy as Wall Street Analysts Look Optimistic?
The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
These 2 Top Dividend Stocks Are Finally Rebounding, and There Might Be More Upside Ahead
It's hard to keep these longtime winners down for too long.
3 Growth Stocks to Invest $1,000 Right Now
Market leaders riding secular tailwinds are likely to be profitable long-term investments.
This Is What Whales Are Betting On Eli Lilly - Eli Lilly ( NYSE:LLY )
Investors with a lot of money to spend have taken a bullish stance on Eli Lilly ( NYSE: LLY ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms - SPDR Dow Jones Industrial Average ETF ( ARCA:DIA ) , First Trust Nasdaq Pharmaceuticals ETF ( NASDAQ:FTXH )
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?
The pharmaceutical company had a clinical setback earlier this year, but that's now in the rearview mirror.
Where Will Recursion Pharmaceuticals Be in 5 Years?
Could investing in this stock be an underrated way to profit from the rapidly expanding AI industry?
Amgen Expands US Manufacturing Network Amid New Tariff Policy - Amgen ( NASDAQ:AMGN )
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc ( NASDAQ: AMGN ) announced a $650 million expansion of its U.S. manufacturing network.
Your AstraZeneca Medicine Could Be Cheaper As Much As 70% - AstraZeneca ( NASDAQ:AZN )
AstraZeneca Plc ( NASDAQ: AZN ) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery.
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs - Apple ( NASDAQ:AAPL )
To gain an edge, this is what you need to know today. Please click here for a chart of SPDR S&P 500 ETF Trust ( NYSE: SPY ) which represents the benchmark stock market index S&P 500 ( SPX ) . 100% tariffs on pharmaceuticals unless the company is building a manufacturing plant in the U.S.
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
3 Strong-Buy Dividend Growth Stocks
All three of these stocks pay fast-growing dividends.
Trump's Drug Tariffs 'A Meaningful Commercial Hit' For Americans, Says Analyst - Eli Lilly ( NYSE:LLY ) , Bristol-Myers Squibb ( NYSE:BMY )
President Donald Trump's proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly Big Pharma, remains displeased.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
FDA Approves Eli Lilly's Drug For Advanced Breast Cancer - Eli Lilly ( NYSE:LLY )
On Thursday, the U.S. Food and Drug Administration ( FDA ) approved Eli Lilly and Co.'s ( NYSE: LLY ) Inluriyo ( imlunestrant ) for adults with estrogen receptor-positive ( ER+ ) , human epidermal growth factor receptor 2-negative ( HER2- ) , ESR1-mutated advanced or metastatic breast cancer ( ...
Here is What to Know Beyond Why Eli Lilly and Company ( LLY ) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know.
Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story.
Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? - Eli Lilly ( NYSE:LLY )
Eli Lilly and Company ( NYSE: LLY ) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The termination is a setback for Lilly's obesity pipeline among growing investor ...
AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?
AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch - Eli Lilly ( NYSE:LLY )
On Wednesday, Eli Lilly & Co. ( NYSE: LLY ) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The company cited strategic business reasons for halting the trial, though a parallel study in non-diabetic obesity ...
Does This Acquisition Make Pfizer Stock a Great Buy?
There's an opportunity to get in on the weight-loss drug craze at a reasonable price.
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.
1 Reason Novo Nordisk ( NVO ) Is 1 of the Best Healthcare Stocks You Can Buy Today
The latest data from the company's oral weight loss drug is bullish for the stock.
Does Eli Lilly's New $5 Billion Drug Manufacturing Facility Make It a Long-Term Buy?
Once up and running, it and other projects should make the company's supply chain stronger.
What's Going On With Eli Lilly Stock Wednesday - Eli Lilly ( NYSE:LLY )
Eli Lilly and Co. LLY CEO Dave Ricks strongly criticized the United Kingdom's approach to drug pricing, describing it as "probably the worst country in Europe" for pharmaceutical prices. He warned that patients may miss out on new medicines if conditions do not improve.
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.
Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset - Eli Lilly ( NYSE:LLY ) , Direxion Daily Healthcare Bull 3X Shares ( ARCA:CURE )
Amid rising concerns about stagflation, investors have continued to bid up the equities sector. As evidence, the benchmark S&P 500 sector is up over 13% year-to-date. However, the concern is that most of these tremendous gains are now concentrated in an elite minority of tech players known as the ...
The Zacks Analyst Blog Highlights Apple, Eli Lilly, Chevron and Monarch Cement
Apple, Eli Lilly, Chevron, and Monarch Cement show mixed performance, with growth in services, strong drug demand and strategic acquisitions.
Time to Buy Pfizer ( PFE ) or Metsera ( MTSR ) Stock?
Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).
Eli Lilly ( LLY ) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Eli Lilly (LLY) stood at $746.98, denoting a -1.06% move from the preceding trading day.
Top Analyst Reports for Apple, Eli Lilly & Chevron
Apple grows Services with over 1B subscribers, while Eli Lilly and Chevron face mixed industry and market dynamics.
Can PFE Successfully Return to the Obesity Space With Metsera Buyout?
Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.
Unpacking the Latest Options Trading Trends in Eli Lilly - Eli Lilly ( NYSE:LLY )
Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 81 unusual trades. Delving into the details, we found 33% of traders were bullish, while 38% showed bearish tendencies.
Roche Targets Top Spot In Weight Loss Drug Market - Roche Holding ( OTC:RHHBY )
Roche Holdings AG RHHBY on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes competition with Eli Lilly And Co. LLY and Novo Nordisk A/S NVO.
Is Eli Lilly Stock a Buy After Gaining 10% in 1 Month?
The drugmaker continues to lead the increasingly competitive market for weight management drugs.
Should You Invest in the VanEck Pharmaceutical ETF ( PPH ) ?
Sector ETF report for PPH ...
2 Magnificent S&P 500 Dividend Stocks Down 7% and 19% to Buy and Hold Forever
These two underperforming stocks remain attractive for long-term dividend-seeking investors.
Boost Your Portfolio With These Top-Ranked ETFs
With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
